AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15303141 — intervention group
Group type: COMPARATOR
Intervention: MBT appliance with two-step retraction
Number of subjects: 37
Study 11952200 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral Couples Therapy (BCT)
Number of subjects: 135
Study 11952200 — intervention group
Group type: COMPARATOR
Intervention: Individual-Based Treatment (IBT)
Number of subjects: 135
Study 11952200 — intervention group
Group type: COMPARATOR
Intervention: Couples-Based Psychoeducational Attention Control Treatment (PACT)
Number of subjects: 135
Study 9608988 — intervention group
Group type: EXPERIMENTAL
Intervention: 50% nitrous oxide in oxygen
Number of subjects: 32
Study 9608988 — intervention group
Group type: COMPARATOR
Intervention: Oxygen
Number of subjects: 32
Study 7618938 — intervention group
Group type: EXPERIMENTAL
Intervention: Length measurement at birth
Number of subjects: 38
Study 7618938 — intervention group
Group type: EXPERIMENTAL
Intervention: Length measurement at 6 weeks
Number of subjects: 38
Study 7618938 — intervention group
Group type: EXPERIMENTAL
Intervention: Length measurement at 8 months
Number of subjects: 38
Study 2696150 — intervention group
Group type: EXPERIMENTAL
Intervention: Amalgam fillings
Number of subjects: 154
Study 2696150 — intervention group
Group type: COMPARATOR
Intervention: Castings
Number of subjects: 154
Study 848704 — intervention group
Group type: EXPERIMENTAL
Intervention: Premedication with atropine and diazepam after pre-operative starvation in hot weather
Number of subjects: 0
Study 848704 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-operative starvation in hot weather
Number of subjects: 0
Study 848704 — intervention group
Group type: COMPARATOR
Intervention: Pre-operative starvation and premedication in temperate weather
Number of subjects: 0
Study 31847821 — intervention group
Group type: EXPERIMENTAL
Intervention: Sit-stand desk intervention
Number of subjects: 15
Study 28062087 — intervention group
Group type: EXPERIMENTAL
Intervention: SIB (Simultaneous Integrated Boost) of 46.8 or 49.95Gy
Number of subjects: 167
Study 28062087 — intervention group
Group type: COMPARATOR
Intervention: SeB (Sequential Boost) of 10Gy in 4 fractions or 14.88Gy in 6 fractions
Number of subjects: 167
Study 25516395 — intervention group
Group type: EXPERIMENTAL
Intervention: Cuffed nasal endotracheal tubes (RAE by Mallinckrodt)
Number of subjects: 0
Study 25516395 — intervention group
Group type: COMPARATOR
Intervention: Uncuffed nasal endotracheal tubes (nasal AGT NETT by Rüsch)
Number of subjects: 0
Study 23460656 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended cognitive‐behavioral treatment with 9 additional group sessions over a 14‐week period
Number of subjects: 141
Study 23460656 — intervention group
Group type: COMPARATOR
Intervention: Nonextended treatment with 4 monthly smoking status calls
Number of subjects: 141
Study 21560485 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 puffs of salbutamol via the pMDI with Volumatic spacer
Number of subjects: 0
Study 21560485 — intervention group
Group type: EXPERIMENTAL
Intervention: Easyhaler (DPI)
Number of subjects: 0
Study 21560485 — intervention group
Group type: COMPARATOR
Intervention: 0.15 mg/kg of salbutamol nebulized via oxygen (or compressed air)
Number of subjects: 0
Study 19330241 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% lidocaine with epinephrine (1:100,000)
Number of subjects: 59
Study 19330241 — intervention group
Group type: COMPARATOR
Intervention: 2% plain lidocaine
Number of subjects: 59
Study 17368253 — intervention group
Group type: COMPARATOR
Intervention: 5-mm non-shielded-bladed trocars (NSBTs)
Number of subjects: 94
Study 17368253 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-mm dilating-tip trocars (DTTs)
Number of subjects: 94
Study 15716158 — intervention group
Group type: EXPERIMENTAL
Intervention: Studied pictures and corresponding auditory words
Number of subjects: 0
Study 15716158 — intervention group
Group type: COMPARATOR
Intervention: Studied words only
Number of subjects: 0
Study 11970797 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam
Number of subjects: 0
Study 11970797 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9449726 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with pneumothorax (50 patients, 6.9%)
Number of subjects: 725
Study 9449726 — intervention group
Group type: COMPARATOR
Intervention: Patients without pneumothorax (675 patients, 93.1%)
Number of subjects: 725
Study 9449726 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with any air leaks (77 patients, 10.6%)
Number of subjects: 725
Study 9449726 — intervention group
Group type: COMPARATOR
Intervention: Patients without any air leaks (648 patients, 89.4%)
Number of subjects: 725
Study 8732135 — intervention group
Group type: EXPERIMENTAL
Intervention: Fuchunpian with radiotherapy
Number of subjects: 60
Study 8732135 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone (Control)
Number of subjects: 60
Study 2665304 — intervention group
Group type: EXPERIMENTAL
Intervention: Transthoracal injections of 0.5% solution of papain
Number of subjects: 109
Study 2665304 — intervention group
Group type: COMPARATOR
Intervention: Active antiinflammatory therapy and bronchosanitation measures
Number of subjects: 109
Study 811182 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B: 1 to 15 meg of potassium acid phosphate per 1,000 K cal
Number of subjects: 19
Study 811182 — intervention group
Group type: EXPERIMENTAL
Intervention: Group C: 15 to 25 meg of potassium acid phosphate per 1,000 K cal
Number of subjects: 19
Study 811182 — intervention group
Group type: EXPERIMENTAL
Intervention: Group D: Greater than 25 meq of potassium acid phosphate per 1,000 K cal
Number of subjects: 19
Study 811182 — intervention group
Group type: COMPARATOR
Intervention: Group A: No phosphate additive
Number of subjects: 19
Study 31435957 — intervention group
Group type: EXPERIMENTAL
Intervention: New powdered human milk fortifier
Number of subjects: 153
Study 31435957 — intervention group
Group type: COMPARATOR
Intervention: Control fortifier
Number of subjects: 153
Study 31435957 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups combined
Number of subjects: 153
Study 31266245 — intervention group
Group type: EXPERIMENTAL
Intervention: TPSR program for 8 months
Number of subjects: 85
Study 31266245 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 85
Study 28483190 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment once per week for 10 weeks
Number of subjects: 25
Study 28483190 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment
Number of subjects: 25
Study 26509984 — intervention group
Group type: EXPERIMENTAL
Intervention: Freeze-Dried Acellular Dermal Matrix (FDADM)
Number of subjects: 2
Study 26509984 — intervention group
Group type: EXPERIMENTAL
Intervention: Solvent-Dehydrated Acellular Dermal Matrix (SDADM)
Number of subjects: 2
Study 23028039 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended letrozole (LET)
Number of subjects: 5166
Study 23028039 — intervention group
Group type: COMPARATOR
Intervention: Switch from placebo (PLAC) to extended letrozole (LET)
Number of subjects: 5166
Study 21196688 — intervention group
Group type: EXPERIMENTAL
Intervention: RN‐HSG with small Albures particles
Number of subjects: 10
Study 21196688 — intervention group
Group type: EXPERIMENTAL
Intervention: RN‐HSG with large MAASOL particles
Number of subjects: 10
Study 21196688 — intervention group
Group type: EXPERIMENTAL
Intervention: RN‐HSG during peri-ovulatory period
Number of subjects: 10
Study 19493408 — intervention group
Group type: EXPERIMENTAL
Intervention: Ulinastatin (UTI) plus Thymosin alpha1 (Talpha1)
Number of subjects: 114
Study 19493408 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Group B)
Number of subjects: 114
Study 15588519 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% N-acetylcarnosine (NAC) lubricant eye drops
Number of subjects: 137
Study 15588519 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 137
Study 10351466 — intervention group
Group type: EXPERIMENTAL
Intervention: Bi-annual, house-to-house re-treatment schedule free of charge using research project staff
Number of subjects: 0
Study 10351466 — intervention group
Group type: EXPERIMENTAL
Intervention: Free re-treatment service via sentinel dipping stations
Number of subjects: 0
Study 10351466 — intervention group
Group type: EXPERIMENTAL
Intervention: Social marketing approach with cost-retrieval for net re-treatment services
Number of subjects: 0
Study 7564436 — intervention group
Group type: EXPERIMENTAL
Intervention: External papaverine application (1.5 mg/ml)
Number of subjects: 78
Study 7564436 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraluminal papaverine application with heparinized blood (1.5 mg/ml) injected once
Number of subjects: 78
Study 7564436 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraluminal papaverine application with heparinized blood (1.5 mg/ml) injected twice
Number of subjects: 78
Study 7564436 — intervention group
Group type: COMPARATOR
Intervention: Control group (submersion in papaverine solution only)
Number of subjects: 78
Study 1979092 — intervention group
Group type: EXPERIMENTAL
Intervention: Hawksley random zero sphygmomanometer
Number of subjects: 0
Study 1979092 — intervention group
Group type: EXPERIMENTAL
Intervention: UK Hawksley random zero sphygmomanometer
Number of subjects: 0
Study 1979092 — intervention group
Group type: EXPERIMENTAL
Intervention: US Hawksley random zero sphygmomanometer
Number of subjects: 0
Study 1979092 — intervention group
Group type: COMPARATOR
Intervention: Standard sphygmomanometers
Number of subjects: 0
Study 6113993 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 gm of 5% nonoxynol‐9 vaginal cream (Conceptrol) for 14 days
Number of subjects: 32
Study 6113993 — intervention group
Group type: COMPARATOR
Intervention: 2.5 gm of the cream base alone for 14 days
Number of subjects: 32
Study 6113993 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 32
Study 31543350 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab treatment in BRVO
Number of subjects: 386
Study 31543350 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab treatment in CRVO
Number of subjects: 386
Study 28590329 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritonavir-boosted atazanavir, darunavir, or raltegravir with tenofovir/emtricitabine backbone
Number of subjects: 235
Study 25666002 — intervention group
Group type: EXPERIMENTAL
Intervention: Honey dressing after debridement
Number of subjects: 72
Study 25666002 — intervention group
Group type: COMPARATOR
Intervention: Control group (no honey dressing)
Number of subjects: 72
Study 25022125 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical acupoint stimulation combined with infusion of propofol (group A)
Number of subjects: 90
Study 25022125 — intervention group
Group type: COMPARATOR
Intervention: Simple propofol (group C)
Number of subjects: 90
Study 20878849 — intervention group
Group type: EXPERIMENTAL
Intervention: Prescription sedative/hypnotics
Number of subjects: 219
Study 20878849 — intervention group
Group type: EXPERIMENTAL
Intervention: OTC analgesics
Number of subjects: 219
Study 20878849 — intervention group
Group type: EXPERIMENTAL
Intervention: Any sleep aid
Number of subjects: 219
Study 18720067 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined surgical and corticosteroid treatment (oral prednisolone for 10 days, nasal budesonide for 1 month, followed by nasal steroids for 1 year)
Number of subjects: 32
Study 18720067 — intervention group
Group type: COMPARATOR
Intervention: Medical treatment alone (not specified in detail)
Number of subjects: 32
Study 18720067 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined surgical and corticosteroid treatment
Number of subjects: 32
Study 17524620 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Remediation Therapy (CRT)
Number of subjects: 40
Study 17524620 — intervention group
Group type: COMPARATOR
Intervention: Standard Care
Number of subjects: 40
Study 15454647 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive care plus cisplatin-based chemotherapy (C)
Number of subjects: 725
Study 15454647 — intervention group
Group type: COMPARATOR
Intervention: Supportive care alone (NoC)
Number of subjects: 725
Study 11442535 — intervention group
Group type: EXPERIMENTAL
Intervention: Gasless laparoscopic cholecystectomy
Number of subjects: 50
Study 11442535 — intervention group
Group type: COMPARATOR
Intervention: Conventional laparoscopic cholecystectomy
Number of subjects: 50
Study 9879412 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral administration of 300 mg/day suplatast tosilate alone
Number of subjects: 83
Study 9879412 — intervention group
Group type: COMPARATOR
Intervention: Immunotherapy using standardized D. farinae alone
Number of subjects: 83
Study 9879412 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunotherapy together with concurrent oral administration of 300 mg/day suplatast tosilate
Number of subjects: 83
Study 7986713 — intervention group
Group type: EXPERIMENTAL
Intervention: Clodronate 2.4 g daily for 24 months
Number of subjects: 350
Study 7986713 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 24 months
Number of subjects: 350
Study 30198102 — intervention group
Group type: EXPERIMENTAL
Intervention: Dutasteride 0.5 mg + tamsulosin 0.2 mg
Number of subjects: 607
Study 30198102 — intervention group
Group type: COMPARATOR
Intervention: Tamsulosin 0.2 mg
Number of subjects: 607
Study 26651495 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole 400 mg daily for 7 days/month (two pulses for fingernails and three pulses for toenails)
Number of subjects: 90
Study 26651495 — intervention group
Group type: COMPARATOR
Intervention: Terbinafine 500 mg daily for 7 days/month (two pulses for fingernails and three pulses for toenails)
Number of subjects: 90
Study 26651495 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole
Number of subjects: 90
Study 26651495 — intervention group
Group type: COMPARATOR
Intervention: Terbinafine
Number of subjects: 90
Study 26634453 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous injections of botulinum toxin type A
Number of subjects: 0
Study 26634453 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 0
Study 24184035 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine niosomal gel formulation (20mg in 20% w/v Pluronic F‐127 gel), applied once daily for 4 months
Number of subjects: 16
Study 24184035 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 16
Study 20685528 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-ligating bracket system (SmartClip)
Number of subjects: 66
Study 20685528 — intervention group
Group type: COMPARATOR
Intervention: Conventional appliance (Victory)
Number of subjects: 66
Study 19265345 — intervention group
Group type: COMPARATOR
Intervention: 3‐mL conventional syringe
Number of subjects: 320
Study 19265345 — intervention group
Group type: COMPARATOR
Intervention: 10‐mL conventional syringe
Number of subjects: 320
Study 19265345 — intervention group
Group type: COMPARATOR
Intervention: 3‐mL RPD
Number of subjects: 320
Study 19265345 — intervention group
Group type: COMPARATOR
Intervention: 10‐mL RPD
Number of subjects: 320
Study 19265345 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-handed operation
Number of subjects: 320
Study 19265345 — intervention group
Group type: COMPARATOR
Intervention: 1-handed operation
Number of subjects: 320
Study 17313606 — intervention group
Group type: EXPERIMENTAL
Intervention: Galantamine
Number of subjects: 65
Study 14969020 — intervention group
Group type: EXPERIMENTAL
Intervention: Aquacel
Number of subjects: 50
Study 14969020 — intervention group
Group type: COMPARATOR
Intervention: Wet-to-dry gauze
Number of subjects: 50
Study 11327191 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate dose of alcohol
Number of subjects: 169
Study 11327191 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 169
Study 9497117 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-invasive electrical stimulation, performed at home for one hour daily for a mean period of 45 days
Number of subjects: 50
Study 9497117 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 7514874 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrendipine (20 mg/d)
Number of subjects: 20
Study 7514874 — intervention group
Group type: COMPARATOR
Intervention: Enalapril (10 mg/d)
Number of subjects: 20
Study 3074464 — intervention group
Group type: EXPERIMENTAL
Intervention: Norfloxacin 400 mg b.i.d.
Number of subjects: 450
Study 3074464 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-trimoxazole (160 mg trimethoprim + 800 mg sulphamethoxazole) b.i.d.
Number of subjects: 450
Study 3074464 — intervention group
Group type: COMPARATOR
Intervention: Placebo b.i.d.
Number of subjects: 450
Study 29769203 — intervention group
Group type: EXPERIMENTAL
Intervention: DPP-IV inhibitor alogliptin (early period up to 6 months)
Number of subjects: 5380
Study 29769203 — intervention group
Group type: EXPERIMENTAL
Intervention: DPP-IV inhibitor alogliptin (chronic period 6 months to end of follow-up)
Number of subjects: 5380
Study 29769203 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 5380
Study 27124177 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided neoadjuvant chemotherapy (guided‐NACT)
Number of subjects: 0
Study 27124177 — intervention group
Group type: COMPARATOR
Intervention: Conventional neoadjuvant chemotherapy (conventional‐NACT)
Number of subjects: 0
Study 25703119 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast-induced acute kidney injury (CI-AKI) in stable CAD patients
Number of subjects: 1918
Study 25703119 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast-induced acute kidney injury (CI-AKI) in ACS patients
Number of subjects: 1918
Study 25703119 — intervention group
Group type: EXPERIMENTAL
Intervention: CI-AKI
Number of subjects: 1918
Study 25703119 — intervention group
Group type: EXPERIMENTAL
Intervention: ΔSCr of 35%
Number of subjects: 1918
Study 23645606 — intervention group
Group type: EXPERIMENTAL
Intervention: mobile CM (mCM)
Number of subjects: 22
Study 23645606 — intervention group
Group type: COMPARATOR
Intervention: yoked control (noncontingent 4-week mCM)
Number of subjects: 22
Study 19941691 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally adapted lifestyle education including diet and physical activity over 7 months.
Number of subjects: 198
Study 19941691 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 198
Study 19700263 — intervention group
Group type: EXPERIMENTAL
Intervention: Mecamylamine (10mg/day)
Number of subjects: 14
Study 19700263 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 16155272 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium supplement (450 mg)
Number of subjects: 27
Study 12796524 — intervention group
Group type: EXPERIMENTAL
Intervention: Levodopa infusion
Number of subjects: 7
Study 10494457 — intervention group
Group type: EXPERIMENTAL
Intervention: CI-988 100 mg TID for six weeks
Number of subjects: 41
Study 10494457 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 8888302 — intervention group
Group type: EXPERIMENTAL
Intervention: Shaded surfaces
Number of subjects: 0
Study 8888302 — intervention group
Group type: EXPERIMENTAL
Intervention: Line-drawn surfaces
Number of subjects: 0
Study 8888302 — intervention group
Group type: EXPERIMENTAL
Intervention: Textured surfaces
Number of subjects: 0
Study 8888302 — intervention group
Group type: EXPERIMENTAL
Intervention: Explicit surface boundaries
Number of subjects: 0
Study 8888302 — intervention group
Group type: EXPERIMENTAL
Intervention: Surface cues
Number of subjects: 0
Study 1848169 — intervention group
Group type: EXPERIMENTAL
Intervention: L-arginine hydrochloride (0.5 g h-1 kg-1 body weight)
Number of subjects: 13
Study 1848169 — intervention group
Group type: EXPERIMENTAL
Intervention: L-lysine hydrochloride (0.44 g h-1 kg-1 body weight)
Number of subjects: 13
Study 1848169 — intervention group
Group type: COMPARATOR
Intervention: Baseline clearance of PGC
Number of subjects: 13
Study 1848169 — intervention group
Group type: COMPARATOR
Intervention: PGA-5
Number of subjects: 13
Study 1848169 — intervention group
Group type: COMPARATOR
Intervention: PGA-4
Number of subjects: 13
Study 1848169 — intervention group
Group type: COMPARATOR
Intervention: PGA-3
Number of subjects: 13
Study 6612181 — intervention group
Group type: EXPERIMENTAL
Intervention: Ornipressin 5 IU/10 mls lidocaine
Number of subjects: 127
Study 31675538 — intervention group
Group type: EXPERIMENTAL
Intervention: Central European diet (CED)
Number of subjects: 144
Study 31675538 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet (MED)
Number of subjects: 144
Study 29604599 — intervention group
Group type: EXPERIMENTAL
Intervention: Garlic extract (GE) 400 mg daily for 3 months
Number of subjects: 92
Study 26887327 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training (12 weeks of gym-based, personalized, and supervised exercise)
Number of subjects: 13
Study 26887327 — intervention group
Group type: COMPARATOR
Intervention: Standard care alone (control group)
Number of subjects: 13
Study 25015436 — intervention group
Group type: COMPARATOR
Intervention: Valsartan/Amlodipine immediate release tablets (film-coated)
Number of subjects: 0
Study 25015436 — intervention group
Group type: COMPARATOR
Intervention: Reference brand product
Number of subjects: 0
Study 22595826 — intervention group
Group type: EXPERIMENTAL
Intervention: Health Utilities Index Mark 3 (HUI3) score at 60 days
Number of subjects: 439
Study 22595826 — intervention group
Group type: EXPERIMENTAL
Intervention: HUI3 ambulation, emotion, cognition, and pain attribute scores
Number of subjects: 439
Study 19721013 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic blood transfusion with desferrioxamine chelation
Number of subjects: 271
Study 17352516 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin 100 or 200mg once daily
Number of subjects: 0
Study 17352516 — intervention group
Group type: COMPARATOR
Intervention: Sitagliptin monotherapy
Number of subjects: 0
Study 17352516 — intervention group
Group type: COMPARATOR
Intervention: Sitagliptin as add-on therapy to metformin or pioglitazone
Number of subjects: 0
Study 17352516 — intervention group
Group type: COMPARATOR
Intervention: Sitagliptin as add-on therapy to metformin
Number of subjects: 0
Study 17352516 — intervention group
Group type: COMPARATOR
Intervention: Sitagliptin
Number of subjects: 0
Study 15111779 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily iron supplementation (1 mg/kg daily)
Number of subjects: 79
Study 15111779 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly iron supplementation (7 mg/kg weekly)
Number of subjects: 79